Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2024

09.01.2024 | REVIEW

Deciphering cellular plasticity in pancreatic cancer for effective treatments

verfasst von: Md. Hafiz Uddin, Dingqiang Zhang, Irfana Muqbil, Bassel F. El-Rayes, Herbert Chen, Philip A. Philip, Asfar S. Azmi

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Cellular plasticity and therapy resistance are critical features of pancreatic cancer, a highly aggressive and fatal disease. The pancreas, a vital organ that produces digestive enzymes and hormones, is often affected by two main types of cancer: the pre-dominant ductal adenocarcinoma and the less common neuroendocrine tumors. These cancers are difficult to treat due to their complex biology characterized by cellular plasticity leading to therapy resistance. Cellular plasticity refers to the capability of cancer cells to change and adapt to different microenvironments within the body which includes acinar-ductal metaplasia, epithelial to mesenchymal/epigenetic/metabolic plasticity, as well as stemness. This plasticity allows heterogeneity of cancer cells, metastasis, and evasion of host’s immune system and develops resistance to radiation, chemotherapy, and targeted therapy. To overcome this resistance, extensive research is ongoing exploring the intrinsic and extrinsic factors through cellular reprogramming, chemosensitization, targeting metabolic, key survival pathways, etc. In this review, we discussed the mechanisms of cellular plasticity involving cellular adaptation and tumor microenvironment and provided a comprehensive understanding of its role in therapy resistance and ways to overcome it.
Literatur
1.
Mizrahi, J. D., et al. (2020). Pancreatic cancer. Lancet, 395(10242), 2008–2020.PubMed
2.
Siegel, R. L., et al. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.PubMed
3.
Hidalgo, M., et al. (2015). Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology, 15(1), 8–18.PubMed
4.
Schober, M., et al. (2014). Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel), 6(4), 2137–2154.PubMed
5.
WHO Classification of Tumours Editorial Board. (2019). Digestive System Tumours: WHO Classification of Tumours, 5th ed. Vol. 1.
6.
Stewart, B. W., et al. (2014). World Cancer Report 2014: World Cancer Reports.
7.
Pishvaian, M. J., & Brody, J. R. (2017). Therapeutic implications of molecular subtyping for pancreatic cancer. Oncology (Williston Park), 31(3), 159–66. 168.PubMed
8.
Fitzgerald, T. L., et al. (2008). Changing incidence of pancreatic neoplasms: A 16-year review of statewide tumor registry. Pancreas, 37(2), 134–138.PubMed
9.
Siegel, R. L., et al. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33.PubMed
10.
Gittes, G. K. (2009). Developmental biology of the pancreas: A comprehensive review. Developmental Biology, 326(1), 4–35.PubMed
11.
Rhim, A. D., et al. (2012). EMT and dissemination precede pancreatic tumor formation. Cell, 148(1–2), 349–361.PubMedPubMedCentral
12.
Farrell, A. S., et al. (2017). MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 8(1), 1728.PubMedPubMedCentral
13.
Reichert, M., et al. (2018). Regulation of epithelial plasticity determines metastatic organotropism in pancreatic cancer. Developmental Cell, 45(6), 696-711 e8.PubMedPubMedCentral
14.
Crawford, H. C., Pasca di Magliano, M., & Banerjee, S. (2019). Signaling networks that control cellular plasticity in pancreatic tumorigenesis, progression, and metastasis. Gastroenterology., 156(7), 2073–2084.PubMed
15.
Shen, S., & Clairambault, J. (2020). Cell plasticity in cancer cell populations. F1000Res, 9, 635.
16.
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discovery, 9(7), 837–851.PubMedPubMedCentral
17.
Rambow, F., Marine, J. C., & Goding, C. R. (2019). Melanoma plasticity and phenotypic diversity: Therapeutic barriers and opportunities. Genes & Development, 33(19–20), 1295–1318.
18.
Qin, S., et al. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 5(1), 228.PubMedPubMedCentral
19.
Kemper, K., et al. (2014). Phenotype switching: Tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Research, 74(21), 5937–5941.PubMed
20.
Gupta, P. B., et al. (2019). Phenotypic plasticity: Driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell, 24(1), 65–78.PubMed
21.
Zhuang, X., Zhang, H., & Hu, G. (2019). Cancer and microenvironment plasticity: Double-edged swords in metastasis. Trends in Pharmacological Sciences, 40(6), 419–429.PubMedPubMedCentral
22.
Smigiel, J. M., et al. (2019). Cellular plasticity and metastasis in breast cancer: A pre- and post-malignant problem. Journal of Cancer Metastasis and Treatment, 5, 47.
23.
Contreras-Trujillo, H., et al. (2021). Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. Nature Communications, 12(1), 6522.PubMedPubMedCentral
24.
Li, M., et al. (2020). An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Communications Biology, 3(1), 505.PubMedPubMedCentral
25.
Hinohara, K., & Polyak, K. (2019). Intratumoral heterogeneity: More than just mutations. Trends in Cell Biology, 29(7), 569–579.PubMedPubMedCentral
26.
Sun, X. X., & Yu, Q. (2015). Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica, 36(10), 1219–1227.PubMedPubMedCentral
27.
Nabi, K., & Le, A. (2021). The intratumoral heterogeneity of cancer metabolism. Advances in Experimental Medicine and Biology, 1311, 149–160.PubMedPubMedCentral
28.
Xiao, Z., Dai, Z., & Locasale, J. W. (2019). Metabolic landscape of the tumor microenvironment at single cell resolution. Nature Communications, 10(1), 3763.PubMedPubMedCentral
29.
Lawson, D. A., et al. (2018). Tumour heterogeneity and metastasis at single-cell resolution. Nature Cell Biology, 20(12), 1349–1360.PubMedPubMedCentral
30.
da Silva-Diz, V., et al. (2018). Cancer cell plasticity: Impact on tumor progression and therapy response. Seminars in Cancer Biology, 53, 48–58.PubMed
31.
Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2(6), 442–454.PubMed
32.
Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265–273.PubMed
33.
Farmer, P., et al. (2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15(1), 68–74.PubMed
34.
Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nature Reviews. Clinical Oncology, 14(10), 611–629.PubMedPubMedCentral
35.
Byers, L. A., et al. (2013). An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research, 19(1), 279–290.PubMed
36.
Horn, L. A., Fousek, K., & Palena, C. (2020). Tumor plasticity and resistance to immunotherapy. Trends in Cancer, 6(5), 432–441.PubMedPubMedCentral
37.
Baccelli, I., et al. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 31(6), 539–544.PubMed
38.
Aktas, B., et al. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research, 11(4), R46.PubMedPubMedCentral
39.
Micalizzi, D. S., et al. (2009). The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of Clinical Investigation, 119(9), 2678–2690.PubMedPubMedCentral
40.
Kong, D., Hughes, C. J., & Ford, H. L. (2020). Cellular plasticity in breast cancer progression and therapy. Frontiers in Molecular Biosciences, 7, 72.PubMedPubMedCentral
41.
Ayob, A. Z., & Ramasamy, T. S. (2018). Cancer stem cells as key drivers of tumour progression. Journal of Biomedical Science, 25(1), 20.PubMedPubMedCentral
42.
PerusinaLanfranca, M., et al. (2020). Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice. Gastroenterology, 158(5), 1417-1432 e11.
43.
Quilichini, E., et al. (2019). Pancreatic ductal deletion of Hnf1b disrupts exocrine homeostasis, leads to pancreatitis, and facilitates tumorigenesis. Cellular and Molecular Gastroenterology and Hepatology, 8(3), 487–511.PubMedPubMedCentral
44.
Tanaka, M., et al. (2012). International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology, 12(3), 183–197.PubMed
45.
Strobel, O., et al. (2007). Beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivo. Proceedings of the National Academy of Sciences of the United States of America, 104(11), 4419–4424.PubMedPubMedCentral
46.
Grippo, P. J., et al. (2003). Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Research, 63(9), 2016–2019.PubMed
47.
Tuveson, D. A., et al. (2006). Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Research, 66(1), 242–247.PubMed
48.
Liou, G. Y., et al. (2013). Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. Journal of Cell Biology, 202(3), 563–577.PubMedPubMedCentral
49.
Logsdon, C. D., & Ji, B. (2009). Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clinical Gastroenterology and Hepatology, 7(11 Suppl), S40–S43.PubMedPubMedCentral
50.
Liou, G. Y., et al. (2016). Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. Cell Reports, 14(10), 2325–2336.PubMed
51.
Hezel, A. F., et al. (2008). Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Molecular and Cellular Biology, 28(7), 2414–2425.PubMedPubMedCentral
52.
Sandgren, E. P., et al. (1990). Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell, 61(6), 1121–1135.PubMed
53.
Liu, J., et al. (2016). TGF-beta1 promotes acinar to ductal metaplasia of human pancreatic acinar cells. Science and Reports, 6, 30904.
54.
Liou, G. Y., et al. (2015). Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. Nature Communications, 6, 6200.PubMed
55.
Means, A. L., et al. (2005). Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development, 132(16), 3767–3776.PubMed
56.
Shi, G., et al. (2013). Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene, 32(15), 1950–1958.PubMed
57.
Wei, D., et al. (2016). KLF4 is essential for induction of cellular identity change and acinar-to-ductal reprogramming during early pancreatic carcinogenesis. Cancer Cell, 29(3), 324–338.PubMedPubMedCentral
58.
Baer, R., et al. (2014). Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110alpha. Genes & Development, 28(23), 2621–2635.
59.
Wu, C. Y., et al. (2014). PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology, 147(6), 1405–16 e7.PubMed
60.
Payne, S. N., et al. (2015). PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis, 4(10), e169.PubMedPubMedCentral
61.
Hill, R., et al. (2010). PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Research, 70(18), 7114–7124.PubMedPubMedCentral
62.
Kopp, J. L., et al. (2012). Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell, 22(6), 737–750.PubMedPubMedCentral
63.
Ardito, C. M., et al. (2012). EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell, 22(3), 304–317.PubMedPubMedCentral
64.
Ji, B., et al. (2009). Ras activity levels control the development of pancreatic diseases. Gastroenterology, 137(3), 1072–82. 1082 e1-6.PubMed
65.
Navas, C., et al. (2012). EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell, 22(3), 318–330.PubMedPubMedCentral
66.
Guerra, C., et al. (2011). Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell, 19(6), 728–739.PubMedPubMedCentral
67.
Guerra, C., et al. (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell, 11(3), 291–302.PubMed
68.
Liou, G. Y., et al. (2015). Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discovery, 5(1), 52–63.PubMed
69.
Krebs, A. M., et al. (2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology, 19(5), 518–529.PubMed
70.
Cruz, V. H., et al. (2019). Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. JCI Insight, 5(9), e126117.
71.
Aguilera, K. Y., et al. (2014). Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Research, 74(4), 1032–1044.PubMed
72.
Shintani, Y., et al. (2008). Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. Journal of Cell Biology, 180(6), 1277–1289.PubMedPubMedCentral
73.
Suzuki, K., et al. (2017). Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. Oncotarget, 8(39), 66098–66111.PubMedPubMedCentral
74.
Jeon, H. Y., et al. (2010). Expression patterns of astrocyte elevated gene-1 (AEG-1) during development of the mouse embryo. Gene Expression Patterns, 10(7–8), 361–367.PubMed
75.
Venugopal, A., et al. (2022). EMT molecular signatures of pancreatic neuroendocrine neoplasms. International Journal of Molecular Sciences, 23(21), 13645.PubMedPubMedCentral
76.
Zhou, B., et al. (2021). High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors. BMC Cancer, 21(1), 334.PubMedPubMedCentral
77.
Ikezono, Y., et al. (2017). Pancreatic neuroendocrine tumors and EMT behavior are driven by the CSC marker DCLK1. Molecular Cancer Research, 15(6), 744–752.PubMed
78.
Adamska, A., & Falasca, M. (2018). Epithelial plasticity is crucial for pancreatic cancer metastatic organotropism. Annals of Translational Medicine, 6(Suppl 1), S53.PubMedPubMedCentral
79.
Aiello, N. M., et al. (2018). EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell, 45(6), 681-695 e4.PubMedPubMedCentral
80.
Storz, P. (2017). Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nature Reviews. Gastroenterology & Hepatology, 14(5), 296–304.
81.
Gidekel Friedlander, S. Y., et al. (2009). Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell, 16(5), 379–389.PubMedPubMedCentral
82.
Morris, JPt., et al. (2010). Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. Journal of Clinical Investigation, 120(2), 508–20.PubMedPubMedCentral
83.
Alonso-Curbelo, D., et al. (2021). A gene-environment-induced epigenetic program initiates tumorigenesis. Nature, 590(7847), 642–648.PubMedPubMedCentral
84.
Del Poggetto, E., et al. (2021). Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 373(6561), eabj0486.PubMedPubMedCentral
85.
Li, Y., et al. (2021). Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nature Cancer, 2(1), 49–65.PubMed
86.
Burdziak, C., et al. (2023). Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis. Science, 380(6645), eadd5327.PubMedPubMedCentral
87.
Flavahan, W. A., Gaskell, E., Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357(6348), eaal2380.
88.
Dawson, M. A. (2017). The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science, 355(6330), 1147–1152.PubMed
89.
Xie, W., et al. (2013). Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell, 153(5), 1134–1148.PubMedPubMedCentral
90.
Gifford, C. A., et al. (2013). Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. Cell, 153(5), 1149–1163.PubMedPubMedCentral
91.
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science., 324(5930), 1029–33.PubMedPubMedCentral
92.
Olivares, O., et al. (2017). Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nature Communications, 8, 16031.PubMedPubMedCentral
93.
Guillaumond, F., et al. (2013). Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 110(10), 3919–3924.PubMedPubMedCentral
94.
Lyssiotis, C. A., & Kimmelman, A. C. (2017). Metabolic interactions in the tumor microenvironment. Trends in Cell Biology, 27(11), 863–875.PubMedPubMedCentral
95.
Sousa, C. M., & Kimmelman, A. C. (2014). The complex landscape of pancreatic cancer metabolism. Carcinogenesis, 35(7), 1441–1450.PubMedPubMedCentral
96.
Perera, R. M., & Bardeesy, N. (2015). Pancreatic cancer metabolism: Breaking it down to build it back up. Cancer Discovery, 5(12), 1247–1261.PubMedPubMedCentral
97.
Blum, R., & Kloog, Y. (2014). Metabolism addiction in pancreatic cancer. Cell Death & Disease, 5(2), e1065.
98.
Liang, C., et al. (2016). Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Biochimica et Biophysica Acta, 1866(2), 177–188.PubMed
99.
Bryant, K. L., et al. (2014). KRAS: Feeding pancreatic cancer proliferation. Trends in Biochemical Sciences, 39(2), 91–100.PubMedPubMedCentral
100.
Ying, H., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149(3), 656–670.PubMedPubMedCentral
101.
Slawson, C., Copeland, R. J., & Hart, G. W. (2010). O-GlcNAc signaling: A metabolic link between diabetes and cancer? Trends in Biochemical Sciences, 35(10), 547–555.PubMedPubMedCentral
102.
Stincone, A., et al. (2015). The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biological Reviews of the Cambridge Philosophical Society, 90(3), 927–963.PubMed
103.
Neesse, A., et al. (2011). Stromal biology and therapy in pancreatic cancer. Gut, 60(6), 861–868.PubMed
104.
Casazza, A., et al. (2014). Tumor stroma: A complexity dictated by the hypoxic tumor microenvironment. Oncogene, 33(14), 1743–1754.PubMed
105.
Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6(5), 392–401.PubMed
106.
Xing, Y., et al. (2015). Metabolic reprogramming of the tumour microenvironment. FEBS Journal, 282(20), 3892–3898.PubMed
107.
Yoshida, G. J. (2015). Metabolic reprogramming: The emerging concept and associated therapeutic strategies. Journal of Experimental & Clinical Cancer Research, 34, 111.
108.
Zhao, H., et al. (2016). Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. eLife, 5, e10250.PubMedPubMedCentral
109.
110.
Sada, M., et al. (2016). Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Cancer Letters, 372(2), 210–218.PubMed
111.
Lisanti, M. P., Martinez-Outschoorn, U. E., & Sotgia, F. (2013). Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery. Cell Cycle, 12(17), 2723–2732.PubMedPubMedCentral
112.
Aponte, P. M., & Caicedo, A. (2017). Stemness in cancer: Stem cells, cancer stem cells, and their microenvironment. Stem Cells International, 2017, 5619472.PubMedPubMedCentral
113.
Li, C., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67(3), 1030–1037.PubMed
114.
Patil, K., et al. (2021). The plasticity of pancreatic cancer stem cells: Implications in therapeutic resistance. Cancer and Metastasis Reviews, 40(3), 691–720.PubMed
115.
Di Carlo, C., Brandi, J., & Cecconi, D. (2018). Pancreatic cancer stem cells: Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma. World Journal of Stem Cells, 10(11), 172–182.PubMedPubMedCentral
116.
Hermann, P. C., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323.PubMed
117.
Nair, N., et al. (2017). A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Science and Reports, 7(1), 6838.
118.
Calle, A. S., et al. (2016). A new PDAC mouse model originated from iPSCs-converted pancreatic cancer stem cells (CSCcm). American Journal of Cancer Research, 6(12), 2799–2815.PubMedPubMedCentral
119.
Hassan, G., et al. (2022). Different pancreatic cancer microenvironments convert iPSCs into cancer stem cells exhibiting distinct plasticity with altered gene expression of metabolic pathways. Journal of Experimental & Clinical Cancer Research, 41(1), 29.
120.
Gaur, P., et al. (2011). Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology, 141(5), 1728–1737.PubMed
121.
Krampitz, G. W., et al. (2016). Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 113(16), 4464–4469.PubMedPubMedCentral
122.
Katsuta, E., et al. (2016). CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. International Journal of Oncology, 48(2), 657–669.PubMed
123.
Truong, L. H., & Pauklin, S. (2021). Pancreatic cancer microenvironment and cellular composition: Current understandings and therapeutic approaches. Cancers (Basel), 13(19), 5028.PubMed
124.
Ramon, Y. C. S., et al. (2020). Clinical implications of intratumor heterogeneity: Challenges and opportunities. Journal of Molecular Medicine (Berlin, Germany), 98(2), 161–177.
125.
Lecharpentier, A., et al. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer, 105(9), 1338–1341.PubMedPubMedCentral
126.
Dongre, A., & Weinberg, R. A. (2019). New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology, 20(2), 69–84.PubMed
127.
Fendt, S. M., Frezza, C., & Erez, A. (2020). Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discovery, 10(12), 1797–1807.PubMedPubMedCentral
128.
Venkatesan, S., et al. (2017). Treatment-induced mutagenesis and selective pressures sculpt cancer evolution. Cold Spring Harbor Perspectives in Medicine, 7(8), a026617.PubMedPubMedCentral
129.
Porter, R. L., et al. (2019). Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 116(52), 26835–26845.PubMedPubMedCentral
130.
Bailey, P., et al. (2016). Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), 47–52.PubMed
131.
Collisson, E. A., et al. (2011). Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine, 17(4), 500–503.PubMedPubMedCentral
132.
Moffitt, R. A., et al. (2015). Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 47(10), 1168–1178.PubMedPubMedCentral
133.
Kloesch, B., et al. (2022). A GATA6-centred gene regulatory network involving HNFs and DeltaNp63 controls plasticity and immune escape in pancreatic cancer. Gut, 71(4), 766–777.PubMed
134.
Thankamony, A. P., et al. (2020). Cancer stem cell plasticity - a deadly deal. Frontiers in Molecular Biosciences, 7, 79.PubMedPubMedCentral
135.
Castelli, V., et al. (2021). The great escape: The power of cancer stem cells to evade programmed cell death. Cancers (Basel), 13(2), 328.PubMed
136.
Ciardiello, C., Leone, A., & Budillon, A. (2018). The crosstalk between cancer stem cells and microenvironment is critical for solid tumor progression: The significant contribution of extracellular vesicles. Stem Cells International, 2018, 6392198.PubMedPubMedCentral
137.
Ye, J., et al. (2014). The cancer stem cell niche: Cross talk between cancer stem cells and their microenvironment. Tumour Biology, 35(5), 3945–3951.PubMed
138.
Safa, A. R. (2016). Resistance to cell death and its modulation in cancer stem cells. Critical Reviews in Oncogenesis, 21(3–4), 203–219.PubMedPubMedCentral
139.
Wang, H. F., et al. (2021). Cell fusion in cancer hallmarks: Current research status and future indications. Oncology Letters, 22(1), 530.PubMedPubMedCentral
140.
Dai, J., et al. (2020). Exosomes: Key players in cancer and potential therapeutic strategy. Signal Transduction and Targeted Therapy, 5(1), 145.PubMedPubMedCentral
141.
Roehlecke, C., & Schmidt, M. H. H. (2020). Tunneling nanotubes and tumor microtubes in cancer. Cancers (Basel), 12(4), 857.PubMed
142.
Manjunath, Y., et al. (2020). Tumor-cell-macrophage fusion cells as liquid biomarkers and tumor enhancers in cancer. International Journal of Molecular Sciences, 21(5), 1872.PubMedPubMedCentral
143.
Jang, G., et al. (2022). Direct cell-to-cell transfer in stressed tumor microenvironment aggravates tumorigenic or metastatic potential in pancreatic cancer. NPJ Genomic Medicine, 7(1), 63.PubMedPubMedCentral
144.
Sharma, N., et al. (2020). Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer & Metabolism, 8, 19.
145.
Biancur, D. E., & Kimmelman, A. C. (2018). The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochimica et Biophysica Acta - Reviews on Cancer, 1870(1), 67–75.PubMedPubMedCentral
146.
Boone, B. A., et al. (2015). Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Annals of Surgical Oncology, 22(13), 4402–4410.PubMedPubMedCentral
147.
Van Cutsem, E., et al. (2018). Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer, 143(8), 2053–2064.PubMed
148.
Hayes, T. K., et al. (2016). Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell, 29(1), 75–89.PubMed
149.
Nishi, K., et al. (2016). Inhibition of fatty acid synthesis induces apoptosis of human pancreatic cancer cells. Anticancer Research, 36(9), 4655–4660.PubMed
150.
Tadros, S., et al. (2017). De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. Cancer Research, 77(20), 5503–5517.PubMedPubMedCentral
151.
Shukla, S. K., et al. (2017). MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell, 32(1), 71-87 e7.PubMedPubMedCentral
152.
Biancur, D. E., et al. (2017). Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nature Communications, 8, 15965.PubMedPubMedCentral
153.
Khalaf, K., et al. (2021). Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Frontiers in Immunology, 12, 656364.PubMedPubMedCentral
154.
Poltavets, V., et al. (2018). The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Frontiers in Oncology, 8, 431.PubMedPubMedCentral
155.
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation, 119(6), 1420–1428.PubMedPubMedCentral
156.
Lu, W., & Kang, Y. (2019). Epithelial-mesenchymal plasticity in cancer progression and metastasis. Developmental Cell, 49(3), 361–374.PubMedPubMedCentral
157.
Ribatti, D., Tamma, R., & Annese, T. (2020). Epithelial-mesenchymal transition in cancer: A historical overview. Translational Oncology, 13(6), 100773.PubMedPubMedCentral
158.
Ruivo, C. F., et al. (2022). Extracellular vesicles from pancreatic cancer stem cells lead an intratumor communication network (EVNet) to fuel tumour progression. Gut, 71(10), 2043–2068.PubMed
159.
Cebrian, M. J., et al. (2016). Paradoxical role of HMGB1 in pancreatic cancer: Tumor suppressor or tumor promoter? Anticancer Research, 36(9), 4381–4389.PubMed
160.
Li, J., et al. (2020). Tumor cell-intrinsic USP22 suppresses antitumor immunity in pancreatic cancer. Cancer Immunology Research, 8(3), 282–291.PubMed
161.
Qian, W., et al. (2021). The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Journal of Experimental & Clinical Cancer Research, 40(1), 25.
162.
Huang, C., Du, J., & Xie, K. (2014). FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochimica et Biophysica Acta, 1845(2), 104–116.PubMedPubMedCentral
163.
Zhao, J., et al. (2022). 5-fluorouracil suppresses stem cell-like properties by inhibiting p38 in pancreatic cancer cell line PANC-1. Folia Histochemica et Cytobiologica, 60(1), 55–65.PubMed
164.
Kim, S., et al. (2015). The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. Pancreas, 44(5), 718–727.PubMedPubMedCentral
165.
Peng, L., et al. (2023). Urokinase-type plasminogen activator receptor (uPAR) cooperates with mutated KRAS in regulating cellular plasticity and gemcitabine response in pancreatic adenocarcinomas. Cancers (Basel), 15(5), 1587.PubMed
166.
Wei, D., et al. (2023). A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clinical Cancer Research, 30, 1–8.
167.
Matsubara, S., et al. (2020). Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition. Human Cell, 33(4), 1197–1203.PubMed
168.
Peer, E., Tesanovic, S., & Aberger, F. (2019). Next-generation Hedgehog/GLI pathway inhibitors for cancer therapy. Cancers (Basel), 11(4), 538.PubMed
169.
Nakashima, H., et al. (2006). Nuclear factor-kappaB contributes to Hedgehog signaling pathway activation through sonic Hedgehog induction in pancreatic cancer. Cancer Research, 66(14), 7041–7049.PubMed
170.
Roca, M. S., et al. (2022). HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Journal of Experimental & Clinical Cancer Research, 41(1), 83.
171.
Capeloa, T., et al. (2022). Inhibition of mitochondrial redox signaling with MitoQ prevents metastasis of human pancreatic cancer in mice. Cancers (Basel), 14(19), 4918.PubMed
172.
Viale, A., et al. (2014). Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 514(7524), 628–632.PubMedPubMedCentral
173.
Bao, B., et al. (2012). Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevention Research (Philadelphia, Pa.), 5(3), 355–364.PubMed
174.
Mohammed, A., et al. (2013). Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Translational Oncology, 6(6), 649–659.PubMedPubMedCentral
175.
Lonardo, E., et al. (2013). Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One, 8(10), e76518.PubMedPubMedCentral
176.
Sancho, P., et al. (2015). MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism, 22(4), 590–605.PubMed
177.
Rausch, V., et al. (2010). Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Research, 70(12), 5004–5013.PubMed
178.
Suzuki, S., et al. (2015). JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget, 6(1), 458–470.PubMed
179.
Shankar, S., et al. (2011). Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One, 6(1), e16530.PubMedPubMedCentral
180.
Ben, Q., et al. (2020). A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Journal of Experimental & Clinical Cancer Research, 39(1), 181.
181.
Zhang, Y., et al. (2015). Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget, 6(12), 9999–10015.PubMedPubMedCentral
182.
Hong, S. P., et al. (2009). CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. International Journal of Cancer, 125(10), 2323–2331.PubMed
183.
Yingling, J. M., et al. (2018). Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor. Oncotarget, 9(6), 6659–6677.PubMed
184.
Melisi, D., et al. (2018). Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. British Journal of Cancer, 119(10), 1208–1214.
185.
Zhang, G. N., et al. (2011). Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Letters, 313(2), 137–144.PubMed
Metadaten
Titel
Deciphering cellular plasticity in pancreatic cancer for effective treatments
verfasst von
Md. Hafiz Uddin
Dingqiang Zhang
Irfana Muqbil
Bassel F. El-Rayes
Herbert Chen
Philip A. Philip
Asfar S. Azmi
Publikationsdatum
09.01.2024
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-023-10164-5

Weitere Artikel der Ausgabe 1/2024

Cancer and Metastasis Reviews 1/2024 Zur Ausgabe

Review

Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling

REVIEW

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

EditorialNotes

Preface

REVIEW

The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance

REVIEW

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

REVIEW

Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise